CN117771381B - Nasal cavity active liquid and preparation method and application method thereof - Google Patents
Nasal cavity active liquid and preparation method and application method thereof Download PDFInfo
- Publication number
- CN117771381B CN117771381B CN202311834344.8A CN202311834344A CN117771381B CN 117771381 B CN117771381 B CN 117771381B CN 202311834344 A CN202311834344 A CN 202311834344A CN 117771381 B CN117771381 B CN 117771381B
- Authority
- CN
- China
- Prior art keywords
- nasal cavity
- parts
- colony
- nasal
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003928 nasal cavity Anatomy 0.000 title claims abstract description 196
- 239000007788 liquid Substances 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 34
- 239000006041 probiotic Substances 0.000 claims abstract description 51
- 235000018291 probiotics Nutrition 0.000 claims abstract description 51
- 230000001580 bacterial effect Effects 0.000 claims abstract description 44
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 32
- 239000002318 adhesion promoter Substances 0.000 claims abstract description 30
- 239000002131 composite material Substances 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 239000000341 volatile oil Substances 0.000 claims abstract description 12
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 9
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 9
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 9
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 9
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000003921 oil Substances 0.000 claims abstract description 7
- 244000166675 Cymbopogon nardus Species 0.000 claims abstract description 5
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 27
- 239000001963 growth medium Substances 0.000 claims description 22
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 230000000529 probiotic effect Effects 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 12
- 239000000661 sodium alginate Substances 0.000 claims description 12
- 235000010413 sodium alginate Nutrition 0.000 claims description 12
- 229940005550 sodium alginate Drugs 0.000 claims description 12
- 241000237536 Mytilus edulis Species 0.000 claims description 11
- 230000014759 maintenance of location Effects 0.000 claims description 11
- 235000020638 mussel Nutrition 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960004889 salicylic acid Drugs 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 6
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 6
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 235000015278 beef Nutrition 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 206010013023 diphtheria Diseases 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000011010 flushing procedure Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 108010065152 Coagulase Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 241000192041 Micrococcus Species 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000002949 hemolytic effect Effects 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- -1 polydimethylsiloxane Polymers 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940080352 sodium stearoyl lactylate Drugs 0.000 claims description 2
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 15
- 230000008439 repair process Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 36
- 206010039083 rhinitis Diseases 0.000 description 29
- 230000000694 effects Effects 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 238000004140 cleaning Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000005507 spraying Methods 0.000 description 12
- 102000015728 Mucins Human genes 0.000 description 8
- 108010063954 Mucins Proteins 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000010753 nasal discharge Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010052437 Nasal discomfort Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000007295 Mucin-3 Human genes 0.000 description 1
- 108010008701 Mucin-3 Proteins 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The application relates to a nasal cavity active liquid, a preparation method and a use method thereof. The composition comprises 100 parts by weight of component A and 100 parts by weight of component B (0.01-0.35); the component A consists of the following raw materials in percentage by weight: 1.5 to 7.5 percent of probiotics composite bacterial liquid, 0 to 0.003 percent of peppermint essential oil, 0 to 0.003 percent of grass oil, 0 to 0.003 percent of citronella essential oil, 0.01 to 0.08 percent of surfactant, 1 to 8 percent of moisturizing adhesion promoter and the balance of diluent; the component B is nasal cavity colony composite bacterial liquid. Through the combined use of probiotics and nasal cavity colony, the nasal cavity immunity is enhanced, the colony is repaired, the nasal cavity is relieved and treated, and under the combined action of the moisturizing adhesion promoter, the diluent and the surfactant, part of the nasal cavity active liquid can clean the nasal cavity, impurities are taken away, and the obtained nasal cavity active liquid can clean and repair the nasal cavity colony.
Description
Technical Field
The application relates to the field of biotechnology, in particular to a nasal cavity active liquid, a preparation method and a use method thereof.
Background
The nose is a filter or cleaner which is equivalent to the lung of a human body, the air breathing amount of the human body in one day is up to 15000 liters, and when the human body breathes, dust and bacteria in the air are all in the filtration of fine nasal cilia and remain in the nasal vestibule, so that the self-cleaning function of the nasal cavity is blocked, and a large amount of bacteria are bred. The bacteria in the nasal cavity of human being is 10000 more, more than 400 times more than the bacteria on the closestool, and for the city with poor greening degree, the bacteria in the human body is more.
The human nasal cavity has colony to assist in treating bacteria breeding, and the normal nasal cavity flora forms one balanced relationship with the immune system of human body and has certain protecting effect to prevent invasion of pathogenic microbe and maintain the normal physiological function of nasal cavity. When the balance is broken, the number or type of normal flora changes, possibly causing some nasal diseases or infections.
For example, when the number or kind of normal flora of the nasal cavity is changed, the human body's function of filtering clean air is weakened, and a great amount of bacteria are generated to grow. Therefore, it is easy to cause respiratory diseases such as rhinitis, pharyngolaryngitis, tracheitis, pneumonia, pneumoconiosis, and mycosis, and serious diseases, and also can cause hyposmia, cerebral oxygen supply deficiency, memory deterioration, and reaction capacity deterioration. Particularly, the rhinitis is proved to be 20-30% of the total population of the rhinitis patients in China by researches, so that the maintenance and cleaning of the nasal cavity are important. When the nasal cavity flora is unbalanced, the patients are easy to suffer from upper respiratory tract infection diseases such as rhinitis, nasosinusitis and the like.
Based on the above conditions, the nasal cavity cleaning agent is adopted for cleaning the rhinitis, then nasal cavity spraying rhinitis medicines are matched for treatment, and medicines can be taken for treatment at the same time. In the aspect of nasal cavity cleaning in the current market, sea salt solutions, such as physiological seawater 0.9% sodium chloride solution and high-permeability seawater 2.3 sodium chloride solution, are mainly adopted, and can clean nasal cavities, reduce nasal secretion and dust accumulation, reduce harmful bacteria breeding, improve immunity and relieve nasal cavity drying damage.
However, since nasal cavity itching is easily caused in long-term air conditioning or dry winter, and only short-time relief is achieved by using sea salt solution, it is generally necessary to perform washing several times a day, which is complicated, and the probability of inhaling into nasal cavity is increased by washing several times, which is liable to cause cold, etc.
At present, medicines such as antibiotics, cetirizine, budesonide, fluticasone propionate, mometasone furoate and the like are usually added for treating rhinitis, and although the onset of rhinitis can be reduced, the long-term use is unfavorable for human health, and even the human body can generate drug resistance.
In summary, in the prior art, when relieving or treating rhinitis, the cleaning agent and the spraying medicine are required to be matched for treatment; and when in use, the medicine needs to be cleaned and sprayed, so that the convenience of use is reduced, and the rhinitis relieving or treating effect is poor after the medicine is used. It is necessary to study a nasal cavity active liquid which can realize the cleaning and the relieving of rhinitis attack.
Disclosure of Invention
In order to solve the technical problems, the application provides a nasal cavity active liquid, a preparation method and a use method thereof.
In a first aspect, the application provides a nasal cavity active liquid, which consists of a component A and a component B in a weight ratio of 100 (0.01-0.35);
The component A consists of the following raw materials in percentage by weight:
1.5 to 7.5 percent of probiotics composite bacterial liquid
Peppermint essential oil 0-0.003%
0 To 0.003 percent of grass oil
0 To 0.003 percent of citronella essential oil
Surfactant 0.01-0.08%
1-8% Of moisture retention adhesion promoter
The balance of diluent;
The component B is nasal cavity colony composite bacterial liquid.
The composition of the raw materials and the dosage range of the raw materials are both the preferred choices of the application, wherein the nasal cavity colony composite bacterial liquid consists of beneficial bacteria in the nasal cavity, so that the colony number and colony type in the nasal cavity can be repaired, the colony of the nasal cavity of a human body can be recovered to be normal, and the bacterial breeding in the nasal cavity can be reduced. Thereby slowing down the onset of rhinitis.
Essential oil of peppermint, and components extracted from peppermint by water distillation or subcritical low-temperature extraction. The application has the advantages of using amount, being rich in fresh and light mint flavor and playing a role in smoothing nose. The grass oil and the citronella can cooperate with the peppermint essential oil to achieve a better nose-smoothing effect. When the pregnant woman uses the medicine, the three kinds of medicines can be omitted. The amount of the grass oil, the citronella energy and the mint essential oil in the application is 0-0.003%, and the dosage can be adjusted according to different crowds and the degree of nasal obstruction.
The surfactant can improve the activity of the nasal cavity active liquid, so that the nasal cavity active liquid can easily flow into the nasal cavity to clean the nasal cavity, and the moisturizing adhesion promoter can adhere a small amount of probiotics and nasal cavity colonies into the nasal cavity, plays a role in moisturizing the nasal cavity, and can dilute the diluent to improve the fluidity of the nasal cavity active liquid.
When the nasal cavity active agent is used, a certain amount of nasal cavity active liquid is sprayed into the nasal cavity to fill the nasal cavity, at the moment, part of probiotics and nasal cavity colonies are adhered into the nasal cavity under the action of the moisturizing adhesion promoter, so that 'nasal cavity medicine feeding' is realized, and when the head is inclined, the surfactant promotes the nasal cavity active liquid to flow out from the interior of the nasal cavity, so that the nasal cavity is cleaned.
The probiotic composite bacterial liquid contains a large amount of probiotics, and the probiotics are microorganisms beneficial to body health, can improve the immunity of nasal cavities, strengthen the internal anti-bad bacteria of rhinitis, inhibit the growth of bad bacteria and prevent and reduce upper respiratory tract infection.
The method is similar to the principle that probiotics balance intestinal flora, and can help to regulate nasal flora, enhance immunity of human body and prevent and alleviate upper respiratory tract infection. However, the existing probiotics active liquid has poor effect of relieving rhinitis, is difficult to adhere to the inside of nasal cavity, especially allergic rhinitis, is stimulated, and is easy to sneeze and run, so that the probiotics active liquid is easy to take away. It is difficult to achieve the cleaning effect at the same time.
In summary, the application uses probiotics and nasal cavity colony in a combined way, and restores normal colony of nasal cavity while enhancing immunity of human nasal cavity, has better effect on relieving and treating rhinitis, and makes part of probiotics and nasal cavity colony entering into nasal cavity easily adhere in nasal cavity under the assistance of moisture retention adhesion promoter, thereby reducing colony loss during sneeze while restoring nasal cavity colony, and simultaneously playing the role of nasal cavity moisture retention.
And under the action of the diluent surfactant, part of the nasal cavity active liquid can wash the nasal cavity and take away impurities. Therefore, the nasal cavity active liquid can clean and repair nasal cavity colonies, reduce rhinitis attacks and improve the practicability.
It should be noted that the nasal cavity active liquid of the application does not contain hormone and other medicines, and is suitable for nasal cavity cleaning and auxiliary treatment of rhinitis for patients with lighter rhinitis symptoms; for patients with severe rhinitis symptoms, the nasal cavity can be well cleaned, and the nasal cavity can also be relieved to a certain extent, but in the aspect of treatment, other medicines are required to be assisted for treatment.
In addition, the component A and the component B obtained by the application adopt a quantitative split charging mode, when the nasal cavity active liquid is used, the component A and the component B are required to be mixed to obtain the nasal cavity active liquid, and the obtained nasal cavity active liquid is required to be used within 2 hours. Preferably, the composition is used within 30min, and the effect is better.
Preferably, the diluent is sodium chloride solution with the mass fraction of 0.2-0.5%. The sodium chloride solution with the concentration range can dilute the raw materials, and can also have a sterilizing effect on harmful bacterial colonies in the nasal cavity, so that the cleaning effect of the nasal cavity is improved.
Preferably, the moisturizing adhesion promoter is prepared from the following raw materials in parts by weight:
Sodium alginate 1-5%
Mussel mucin 1-3%
Xanthan gum 1-8%
Carboxyl chitosan 3-8%
Salicylic acid 1-6%
Polyethylene glycol 0.5-1.5%
The balance being water.
The moisturizing adhesion promoter prepared from the raw materials can play a good role in moisturizing and adhesion promotion, can increase the adhesion effect of probiotics and nasal cavity colonies, adhere the probiotics and the nasal cavity colonies to the interior of the nasal cavity, and simultaneously adhere to the nasal cavity to play a good role in moisturizing the nasal cavity,
Sodium alginate, xanthan gum, mussel mucin, polyethylene glycol have better adhesiveness, security, film forming property, moisture retention and the like, salicylic acid and carboxyl chitosan have the functions of resisting bacteria, retaining moisture, inhibiting bacteria and the like, so that the moisture retention adhesion promoter obtained by the sodium alginate, the xanthan gum, the mussel mucin, the polyethylene glycol salicylic acid and the carboxyl chitosan can improve the moisture retention effect of the nasal cavity, and meanwhile, probiotics and the like can be improved to adhere in the nasal cavity, so that the immunity of a human body is improved, the growth of harmful bacterial colonies is inhibited, the bacterial colonies of the nasal cavity are better regulated, and the rhinitis is reduced, so that a certain auxiliary treatment effect is achieved.
The polyethylene glycol has an average molecular weight of 200.
Preferably, the preparation method of the moisturizing adhesion promoter comprises the following steps:
According to the weight portions, salicylic acid and water are weighed and evenly mixed, heated to 50-60 ℃, carboxyl chitosan is added, stirring is carried out for 0.5-1h, sodium alginate, mussel mucin, xanthan gum and polyethylene glycol are sequentially added, stirring is carried out evenly, and sodium citrate is added to adjust the PH value to 6-7, thus obtaining the moisturizing adhesion promoter.
The preparation method is simple to operate and high in production efficiency, and the obtained moisturizing adhesion promoter has good effects of inhibiting bacteria, moisturizing, adhering and the like, can inhibit the growth of harmful bacterial colonies, enables probiotics and the like to be easily adhered to the inside of the nasal cavity, and has good moisturizing effect on the nasal cavity.
Preferably, the probiotic composite bacterial liquid contains one or more bacterial colonies consisting of lactobacillus helveticus, lactobacillus crispatus, lactobacillus plantarum, lactobacillus reuteri, saccharomyces boulardii, bacillus subtilis bigeminal viable bacteria and bifidobacterium.
Lactobacillus helveticus, lactobacillus crispatus, lactobacillus plantarum, lactobacillus reuteri, saccharomyces boulardii, bacillus subtilis bigeminal live bacteria and bifidobacterium are all probiotics, so that the immunity of a human body can be improved, and the breeding of harmful bacteria in the nasal cavity is reduced.
Wherein the lactobacillus reuteri is lactobacillus acidophilus, and the lactobacillus reuteri can promote digestion and absorption of nutrients in vitro and enhance immunity.
The saccharomyces boulardii can promote digestion and absorption of nutrient substances in vitro, regulate and assist nasal cavity to regulate flora, improve immunity, and help relieve symptoms such as runny nose, nasal obstruction, sneeze and the like of rhinitis patients.
The bacillus subtilis bigeminal live bacteria can also improve immunity and play an auxiliary treatment role on symptoms such as nasal obstruction, nasal discharge, sneeze and the like of rhinitis patients.
The bifidobacteria is a gram-positive bacterium, and can form a protective barrier on the inner wall of the nasal cavity of a human body after being used, inhibit the reproduction of rhinitis harmful bacteria and maintain the balance of nasal cavity flora.
When lactobacillus reuteri, saccharomyces boulardii and bifidobacterium are adopted in the application, the weight ratio of the lactobacillus reuteri to the bifidobacterium is 1: (0.5-1): (1-2) can further enhance the immunity of the nasal cavity, inhibit the growth of harmful bacterial colonies, assist the active liquid of bacterial colonies of the nasal cavity and improve the repairing effect on normal bacterial colonies of the nasal cavity.
When lactobacillus helveticus, lactobacillus crispatus, lactobacillus plantarum, lactobacillus reuteri, saccharomyces boulardii and bifidobacterium are adopted, the weight ratio of the lactobacillus helveticus to the lactobacillus crispatus to the lactobacillus plantarum is 1: (1-2): (1-2): (2-3): (1-3): (2-3) can further enhance the immunity of the nasal cavity, inhibit the growth of harmful bacterial colonies, assist the active liquid of the bacterial colonies of the nasal cavity and improve the restoration effect of normal bacterial colonies of the nasal cavity after being used.
Preferably, the nasal cavity colony complex bacterial liquid contains one or more colonies consisting of staphylococcus epidermidis, staphylococcus aureus, pseudo diphtheria bacillus, gram negative bacteria, coagulase negative staphylococcus, pseudo diphtheria corynebacterium, nonpathogenic neisseria, alpha-hemolytic streptococcus, non-hemolytic streptococcus and micrococcus.
The colonies are all common colonies in the nasal cavity. Can repair normal colony of nasal cavity. When the ratio of the staphylococcus epidermidis to the staphylococcus aureus is 1: the colony consisting of (2-3) is used in nasal cavity, can further repair nasal colony, and the obtained nasal cavity active liquid can be used for washing nasal cavity and assisting in treating rhinitis, and is mainly used for adults.
When staphylococcus epidermidis, staphylococcus aureus, pseudo diphtheria bacillus, gram negative bacteria, coagulase negative staphylococcus, alpha-hemolytic streptococcus, non-hemolytic streptococcus and micrococcus are mixed according to the weight ratio of 1: (2.2-3.1): (0.08-0.22): (0.4-0.9): (0.01-0.1): (0.1-0.8): (0.2-0.5), and the obtained nasal cavity active liquid is mainly used for children.
Preferably, the surfactant is one or more of sodium stearyl lactate, polydimethylsiloxane and sodium polyacrylate.
The surfactant with one or more components can improve the fluidity of the nasal cavity active liquid, enable the nasal cavity active liquid to easily flow into the nasal cavity, promote the moisturizing adhesion promoter to adhere the probiotic composite bacterial liquid and the nasal cavity colony culture medium to the nasal cavity, and improve the cleaning effect of the nasal cavity active liquid and the effect of relieving the onset of rhinitis.
In a second aspect, the present application provides a method of preparing a nasal active solution comprising the steps of:
Probiotic composite bacterial liquid: uniformly mixing 0.1-5 parts of probiotics and 10-20 parts of probiotics culture medium according to parts by weight, culturing for 15-24 hours at the temperature of 27-33 ℃, and flushing with sterile normal saline to obtain probiotics composite bacterial liquid;
Nasal cavity colony composite bacterial liquid: weighing 0.1-3 parts of nasal cavity colony and 8-15 parts of nasal cavity colony culture medium according to parts by weight, culturing for 12-18 hours at the temperature of 25-30 ℃ and flushing with sterile physiological saline to obtain nasal cavity colony composite bacterial liquid;
Weighing peppermint essential oil, grass oil, surfactant, moisturizing adhesion promoter and diluent according to weight percentage, mixing uniformly, and adding probiotic compound bacteria solution to mix uniformly to obtain a component A;
When in use, the component A and the component B are weighed according to the weight ratio of 100 (0.01-0.35) and mixed for 10-60s to obtain the nasal cavity active liquid.
Preferably, the probiotic culture medium: according to parts by weight, 1-5 parts of beef extract, 5-15 parts of protein jelly, 18-25 parts of agar, 2-7 parts of sodium chloride and 800-1200 parts of water are uniformly mixed, the PH value is regulated to 6.5-7.5, the mixture is heated to 121-130 ℃, and the mixture is stirred for 15-28min to prepare the probiotic culture medium.
The probiotics culture medium prepared from the raw materials has a good culture effect, and can further promote the growth of probiotics.
Preferably, the nasal colony culture medium: weighing 8-12 parts of peptone, 8-12 parts of beef extract, 3-8 parts of yeast extract, 18-22 parts of glucose, 3-8 parts of sodium acetate, 0.8-1.2 parts of tween-80, 18-22 parts of calcium carbonate and 15-25 parts of agar, adding into distilled water, uniformly mixing, adding 920-1050 parts of distilled water, and sterilizing at 118-123 ℃ and under the pressure of 0.08-0.12MPa for 28-32min to obtain the nasal cavity colony culture medium.
The nasal cavity colony culture medium prepared from the raw materials has a good culture effect and can further promote growth of nasal cavity colonies.
In a third aspect, the present application provides a method of use for a nasal active solution, comprising the steps of: the component A and the component B are contained in a spray bottle according to the weight ratio of 100 (0.01-0.35), and are shaken for 10-60s to obtain nasal cavity active liquid, wherein the nasal cavity active liquid is a nasal cavity active liquid; holding breath, tilting head, spraying active liquid into one nasal cavity with spraying amount of 1-20mL and bending down for 45-75 deg after spraying amount of 1-13s to make the nasal cavity active liquid flow out from the inner part of nasal cavity, wiping nose and keeping clean;
then the active liquid is sprayed into the other nasal cavity, the spraying amount is 1-20mL, after the spraying amount is 1-13s, the nasal cavity active liquid is bent for 45-75 degrees, the nasal cavity active liquid flows out from the inner part of the nasal cavity, the nasal cavity is wiped, the nasal cavity is kept clean, and the use of the nasal cavity active liquid is completed.
The application method can realize the cleaning and the medicine feeding of the nasal cavity at the same time, can relieve the bacterial breeding in the nasal cavity, improve the immunity of human bodies, and simultaneously enhance the growth of beneficial bacterial colonies in the nasal cavity, and repair the nasal cavity uniformly, thereby playing a certain role in auxiliary treatment of rhinitis.
In summary, the application has the following beneficial effects:
1. The application can repair normal colony of nasal cavity while enhancing immunity of human nasal cavity by combining probiotics and nasal colony, has better effect on relieving and treating rhinitis, and can easily adhere part of probiotics and nasal colony entering into nasal cavity to the interior of nasal cavity under the assistance of the moisturizing adhesion promoter, thereby reducing colony loss during sneeze while repairing nasal colony and simultaneously playing the role of moisturizing nasal cavity.
2. Moisturizing effect of nasal cavity can be improved through moisturizing adhesion promoter obtained by sodium alginate, xanthan gum, mussel mucin, polyethylene glycol salicylic acid and carboxyl chitosan, and meanwhile probiotics and the like can be improved to be adhered in the nasal cavity, so that immunity of human body is improved, growth of harmful bacterial colony is inhibited, nasal cavity bacterial colony is better regulated, and rhinitis attack is reduced, and a certain auxiliary treatment effect is achieved.
Detailed Description
The present application will be described in further detail with reference to examples.
Partial sources of raw materials:
TABLE 1 sources of partial raw materials
Preparation example of moisture retention adhesion promoter
Preparation example 1
The moisture retention adhesion promoter is prepared by the following method:
According to weight percentage, 1g of salicylic acid and 82.5g of water are weighed and mixed evenly, heated to55 ℃, 3g of carboxyl chitosan is added, stirred for 0.8h, then 1g of sodium alginate, 3g of mussel mucin, 8g of xanthan gum and 1.5g of polyethylene glycol are added in sequence, stirred evenly, and then sodium citrate is added to adjust the PH value to 6.5, thus obtaining the moisturizing adhesion promoter.
PREPARATION EXAMPLES 2-3
Preparation examples 2 to 3 differ from preparation example 1 in that: the amounts of the raw materials used were varied and are specifically as described in table 2:
TABLE 2 raw material amounts (g) of preparation examples 1-3
| Raw materials | Preparation example 1 | Preparation example 2 | Preparation example 3 |
| Sodium alginate | 1 | 3 | 5 |
| Mussel mucin | 3 | 2 | 1 |
| Xanthan gum | 8 | 5 | 1 |
| Carboxyl chitosan | 3 | 5 | 8 |
| Salicylic acid | 1 | 4 | 6 |
| Polyethylene glycol | 1.5 | 1 | 0.5 |
| Water and its preparation method | 82.5 | 80 | 78.5 |
Preparation of comparative example
Preparation of comparative example 1
The preparation comparative example 1 is different from the preparation example 1 in that: sodium alginate was replaced equally with mussel mucin.
Preparation of comparative example 2
The preparation comparative example 2 is different from the preparation example 1 in that: mussel mucin is replaced with sodium alginate in equal amount.
Preparation of comparative example 3
The preparation comparative example 3 is different from the preparation example 1 in that: the carboxyl chitosan is replaced by sodium alginate in equal quantity.
Examples
Example 1
A method for preparing a nasal cavity active liquid, comprising the following steps:
Probiotic culture medium: 3.0g of beef extract, 10.0g of protein jelly, 20.0g of agar, 5g of sodium chloride and 1000g of water, uniformly mixing, adjusting the pH value to 7, heating to 125 ℃, and stirring for 20min to prepare the probiotic culture medium.
Nasal cavity colony culture medium: 10g of peptone, 8g of beef extract, 5g of yeast extract, 20g of glucose, 5g of sodium acetate, 1g of tween-80, 18g of calcium carbonate and 25g of agar are weighed and added into 1000g of distilled water to be uniformly mixed, and then sterilization treatment is carried out for 30min at the temperature of 120 ℃ and the pressure of 0.1MPa, so as to prepare the cavity colony culture medium.
Nasal cavity colony comprises staphylococcus epidermidis and staphylococcus aureus according to the weight (g) ratio of 1: and 2, weighing and compounding to obtain the product.
The probiotics are prepared from lactobacillus reuteri, saccharomyces boulardii and bifidobacterium according to the weight (g) ratio of 1:0.5: and 2, weighing and compounding to obtain the product.
Probiotic composite bacterial liquid: uniformly mixing 10g of probiotics and 1000g of probiotics culture medium, culturing for 20 hours at the temperature of 30 ℃, and flushing with sterile physiological saline (0.9% sodium chloride by mass fraction) for 3 times to obtain probiotics composite bacterial liquid;
nasal cavity colony culture medium: weighing 10g of nasal cavity colony and 1000g of nasal cavity colony culture solution, culturing for 15h at 30 ℃,
Washing with sterile physiological saline (0.9% sodium chloride by mass fraction) to obtain a nasal cavity colony culture medium;
And (3) a component A: preparing a component A by 10kg of total amount, weighing 0.001% of peppermint essential oil, 0.01% of surfactant (sodium stearoyl lactylate), 2% of moisturizing adhesion promoter obtained in preparation example 1, uniformly mixing with 97.389% of diluent, adding 1.5% of probiotic composite bacterial liquid, and uniformly mixing to obtain the component A.
The diluent is sodium chloride solution with mass fraction of 0.5.
The component B is nasal cavity colony composite bacterial liquid.
The nasal cavity active liquid is obtained by mixing the component A and the component B according to the weight (kg) ratio of 100:0.1.
Examples 2 to 5
Examples 2-5 differ from example 1 in that: the amounts of the nasal active liquid raw materials are different, and are specifically shown in table 3:
TABLE 3 raw materials used in examples 1-5 (%)
Examples 4 to 8
Examples 4-8 differ from example 1 in that: the sources of the moisturizing adhesion promoters are different and are specifically shown in table 4:
TABLE 4 sources of moisturizing adhesion promoters for examples 4-8
| Examples | Moisture retention adhesion promoter source |
| Example 4 | Preparation example 2 |
| Example 5 | Preparation example 3 |
| Example 6 | Preparation of comparative example 1 |
| Example 7 | Preparation of comparative example 2 |
| Example 8 | Preparation of comparative example 3 |
Example 9
Example 9 differs from example 4 in that: the probiotics are prepared from lactobacillus helveticus, lactobacillus crispatus, lactobacillus plantarum, lactobacillus reuteri, saccharomyces boulardii and bifidobacterium according to the weight (g) ratio of 1:1:2:3:2: and 3, weighing and mixing.
Comparative example
Comparative example 1
Comparative example 1 differs from example 1 in that: the moisturizing adhesion promoter is replaced by a diluent in equal quantity.
Comparative example 2
Comparative example 2 is different from example 1 in that: the probiotic composite bacteria liquid is replaced by the diluent in equal quantity.
Comparative example 3
Comparative example 3 is different from example 1 in that: the nasal cavity colony composite bacterial liquid is equivalent to Cheng Yi bacterial liquid.
Comparative example 4
Comparative example 4 differs from example 1 in that: the nasal cavity active liquid is sodium chloride solution with mass fraction of 2.3%.
Application example
Application example 1
A method of use for a nasal active fluid comprising the steps of: the component A and the component B are contained in a spray bottle according to the weight (g) ratio of 100:1, and are shaken for 10s to obtain a nasal cavity active liquid, wherein the nasal cavity active liquid is the nasal cavity active liquid obtained in the embodiment 1; after mixing, the nasal cavity cleaning agent is used within 30min, when in use, breath is held, the head is turned upside down, the active liquid is sprayed into one nasal cavity, the spraying amount is 5mL, after 10s spraying, the nasal cavity active liquid is bent for 60 degrees, so that the nasal cavity active liquid flows out from the interior of the nasal cavity, and the nasal cavity is cleaned, so that the nasal cavity is kept clean;
and then the active liquid is sprayed into the other nasal cavity, the spraying amount is 15mL, after the spraying amount is 10s, the nasal cavity active liquid is bent for 60 degrees, so that the nasal cavity active liquid flows out from the interior of the nasal cavity, the nasal cavity is wiped, the nasal cavity is kept clean, and the use of the nasal cavity active liquid is completed.
Application examples 2 to 13
Application examples 2 to 13 differ from application example 1 in that: the sources of the nasal active solutions vary, as shown in table 5 below;
TABLE 5 nasal cavity active liquid sources of application examples 1-13
Performance test
Detection method/test method
(One) moisture-preserving Effect test
Spreading 5mL of the nasal cavity active liquid obtained in examples 1-9 and comparative example 1 and comparative example 4 on the surface of 5CM pigskin (namely, pigskin after fresh pigskin is placed in an oven at 50 ℃ for 30 min), standing for 10s, standing the pigskin to enable the nasal cavity active liquid on the surface of the pigskin to flow away, so as to obtain pigskin adhered with the nasal cavity active liquid, placing the pigskin adhered with the nasal cavity active liquid and blank pigskin (which is not contacted with the nasal cavity active liquid) in an environment with humidity of 45 ℃ and temperature of 32 ℃, respectively detecting the humidity after 2h, 5h and 10h, wherein the humidity of one surface of the pigskin adhered with the nasal cavity active liquid obtained in examples 1-9 and comparative example 1 and comparative example 4 is marked as a1, the blank pigskin is marked as a2, calculating the humidity relative rate= [ (a 1-a 2)/a 2 ]. Times.100%, and when the humidity relative rate is larger than 100, showing that the surface has better retention than the blank pig skin, and the specific data are shown in table 6;
Table 6 experimental data for examples 1-9 and comparative example 1 and comparative example 4
As can be seen from the combination of example 1 and comparative example 1 and the table 6, the humidity relative rate of example 1 is higher than that of comparative example 1, and the humidity relative rate of example 1 decreases by a small amount with the longer standing time, and when 10 hours are reached, example 1 maintains a good humidity anyway, while the humidity of comparative example 1 is consistent with that of the blank group, thus demonstrating that the addition of the moisturizing adhesion promoter has a good moisturizing effect.
As can be seen from the combination of example 1 and comparative example 4 and the table 6, the humidity relative rate of example 1 is higher than that of comparative example 4, and the humidity relative rate of example 1 is reduced less than that of comparative example 4 as the standing time is prolonged, and when 10 hours are reached, example 1 maintains a better humidity, whereas the humidity of comparative example 4 is consistent with the blank group, and thus, the nasal cavity active solution using the present application has a better moisturizing effect than that using a sodium chloride solution with a mass fraction of 2.3%.
(II) antiallergic detection
Experimental reagent: ovalbumin (ovalbumin, OVA), aluminum hydroxide, physiological saline (0.9% sodium chloride);
experimental animals: female BALB/c mice, 6-8W of week old
Preparation environment: barrier environment
Molding cycle: 4-5 weeks
Moulding method
Each mouse was given 200 μl of OVA solution by intraperitoneal injection on days 1, 7, and 14, respectively.
Excitation process
On days 21-28, each mouse was given daily nasal drops of the challenge OVA solution, 20 μl per nostril drop, for a total of 7 consecutive days. The control mice were given an equivalent amount of physiological saline.
3. Scoring:
scoring criteria: and within 20 minutes after the excitation, grading and recording according to the degree and the frequency of nasal itching, sneeze and nasal discharge.
Scoring time: allergic response index scores were performed after day 0 dosing, and before day 1 sensitization, after days 1,7, 14 sensitization, and after day 21, 28 challenge, and are shown in table 7.
Experimental results: the scores of the symptoms are superimposed, and the total score is greater than 5 and the model is successful.
TABLE 7 scoring criteria
| Scoring of | 0 Part of | 1 Minute | 2 Parts of | 3 Parts of |
| The number of nasal itching times | 0-1 Times/60 min | 0-1 Times per 20min | 2-5 Times/20 min | More than 5 times/20 min |
| Sneeze times | 0-1 Times/60 min | 1-3 | 4-10 | More than 10 times |
| Runny nose | No watery nasal discharge | To the anterior nares | Beyond the anterior naris | Nasal discharge filling up face |
The method for using the nasal cavity active liquid (spraying amount is 1 mL) is used for cleaning the nasal cavity of the mice, the nasal cavity of the mice is used once a day, the states of the mice after 1 day, 7 days and 14 days are observed respectively, and the grading modes are adopted for grading, and the specific is shown in the table 8;
table 8 experimental data for example 1, example 4, example 9, comparative examples 2-4
| Test item | For 1 day | For 7 days | 14 Days | Modeling scoring |
| Example 1 | 5 | 3 | 3 | 8 |
| Example 4 | 4 | 3 | 2 | 8 |
| Example 9 | 3 | 2 | 0 | 8 |
| Comparative example 2 | 7 | 5 | 4 | 8 |
| Comparative example 3 | 6 | 4 | 3 | 8 |
| Comparative example 4 | 8 | 7 | 6 | 8 |
From the data, the nasal cavity active liquid obtained by the application has better effects of cleaning and relieving rhinitis attacks, and can also play a certain role in relieving when only being cleaned by saline, but has poorer role than the nasal cavity active liquid.
The present embodiment is only for explanation of the present application and is not to be construed as limiting the present application, and modifications to the present embodiment, which may not creatively contribute to the present application as required by those skilled in the art after reading the present specification, are all protected by patent laws within the scope of claims of the present application.
Claims (6)
1. The nasal cavity active liquid is characterized by comprising a component A and a component B in a weight ratio of 100 (0.01-0.35);
The component A consists of the following raw materials in percentage by weight:
1.5 to 7.5 percent of probiotics composite bacterial liquid
Peppermint essential oil 0-0.003%
0 To 0.003 percent of grass oil
0 To 0.003 percent of citronella essential oil
Surfactant 0.01-0.08%
1-8% Of moisture retention adhesion promoter
The balance of diluent;
The component B is nasal cavity colony composite bacterial liquid;
The moisturizing adhesion promoter is prepared from the following raw materials in percentage by weight:
sodium alginate 1-5%
Mussel mucin 1-3%
Xanthan gum 1-8%
Carboxyl chitosan 3-8%
Salicylic acid 1-6%
Polyethylene glycol 0.5-1.5%
The balance being water;
The probiotics composite bacterial liquid contains one or more bacterial colonies consisting of lactobacillus helveticus, lactobacillus crispatus, lactobacillus plantarum, lactobacillus reuteri, saccharomyces boulardii, bacillus subtilis bigeminal viable bacteria and bifidobacteria;
The nasal cavity colony composite bacterial liquid contains colonies consisting of one or more of staphylococcus epidermidis, staphylococcus aureus, pseudo diphtheria bacillus, gram negative bacteria, coagulase negative staphylococcus, pseudo diphtheria corynebacterium, nonpathogenic neisseria, alpha-hemolytic streptococcus, non-hemolytic streptococcus and micrococcus.
2. The method for preparing the nasal cavity active liquid according to claim 1, wherein the method for preparing the moisturizing adhesion promoter comprises the following steps:
According to the weight portions, salicylic acid and water are weighed and evenly mixed, heated to 50-60 ℃, carboxyl chitosan is added, stirring is carried out for 0.5-1h, sodium alginate, mussel mucin, xanthan gum and polyethylene glycol are sequentially added, stirring is carried out evenly, and sodium citrate is added to adjust the pH value to 6-7, thus obtaining the moisturizing adhesion promoter.
3. A nasal active fluid according to claim 1, wherein: the surfactant is one or more of sodium stearoyl lactylate, polydimethylsiloxane and sodium polyacrylate.
4. A method of preparing a nasal active fluid according to any one of claims 1 to 3, comprising the steps of:
Probiotic composite bacterial liquid: uniformly mixing 0.1-5 parts of probiotics and 10-20 parts of probiotics culture medium according to parts by weight, culturing for 15-24 hours at the temperature of 27-33 ℃, and flushing with sterile normal saline to obtain probiotics composite bacterial liquid;
Nasal cavity colony composite bacterial liquid: weighing 0.1-3 parts of nasal cavity colony and 8-15 parts of nasal cavity colony culture medium according to parts by weight, culturing for 12-18 hours at the temperature of 25-30 ℃ and flushing with sterile physiological saline to obtain nasal cavity colony composite bacterial liquid;
Weighing peppermint essential oil, grass oil, surfactant, moisturizing adhesion promoter and diluent according to weight percentage, mixing uniformly, and adding probiotic compound bacteria solution to mix uniformly to obtain a component A;
when in use, the component A and the component B are weighed according to the weight ratio of 100 (0.01-0.35) and mixed for 10-60s to obtain the nasal cavity active liquid.
5. A method of preparing a nasal active solution according to claim 4, wherein the probiotic culture medium: according to parts by weight, 1-5 parts of beef extract, 5-15 parts of protein jelly, 18-25 parts of agar, 2-7 parts of sodium chloride and 800-1200 parts of water are uniformly mixed, the pH value is regulated to 6.5-7.5, the mixture is heated to 121-130 ℃, and the mixture is stirred for 15-28min to prepare the probiotic culture medium.
6. A method of preparing a nasal cavity active liquid according to claim 4, wherein the nasal cavity colony culture medium: weighing 8-12 parts of peptone, 8-12 parts of beef extract, 3-8 parts of yeast extract, 18-22 parts of glucose, 3-8 parts of sodium acetate, 0.8-1.2 parts of tween-80, 18-22 parts of calcium carbonate and 15-25 parts of agar, adding into distilled water, uniformly mixing, adding 920-1050 parts of distilled water, and sterilizing at 118-123 ℃ and under the pressure of 0.08-0.12MPa for 28-32min to obtain the nasal cavity colony culture medium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311834344.8A CN117771381B (en) | 2023-12-28 | 2023-12-28 | Nasal cavity active liquid and preparation method and application method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311834344.8A CN117771381B (en) | 2023-12-28 | 2023-12-28 | Nasal cavity active liquid and preparation method and application method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117771381A CN117771381A (en) | 2024-03-29 |
| CN117771381B true CN117771381B (en) | 2024-06-18 |
Family
ID=90386912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311834344.8A Active CN117771381B (en) | 2023-12-28 | 2023-12-28 | Nasal cavity active liquid and preparation method and application method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117771381B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4591810B2 (en) * | 2003-09-19 | 2010-12-01 | 日之出産業株式会社 | Nasal composition for controlling hay fever allergic rhinitis |
| SG11201907043VA (en) * | 2017-01-31 | 2019-08-27 | Univ Industry Cooperation Group Kyung Hee Univ | Novel lactic acid bacteria and use thereof |
| CN110381960A (en) * | 2017-02-02 | 2019-10-25 | 麦克马斯特大学 | The bicarbonate of reinforcing agent as antimicrobial |
| CN106581148A (en) * | 2017-02-28 | 2017-04-26 | 四川艾医生医疗科技有限公司 | Nasal irrigation care solution |
| CN111135141A (en) * | 2020-01-20 | 2020-05-12 | 蓝佳堂生物医药（福建）有限公司 | Preparation method of composite hydrogel for nasal cavity |
-
2023
- 2023-12-28 CN CN202311834344.8A patent/CN117771381B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Microbiological and Histopathological Effects of Nasal Packing Containing Probiotics on Nasal Mucosa;Ozan Gokdogan, et al.;《The Journal of Craniofacial Surgery》;20161130;第27卷(第8期);730-734 * |
| 糠酸莫米松鼻喷雾剂对变应性鼻炎患儿鼻腔黏液菌群的影响;张文渊;朱兆钧;蔡永明;殷亚磊;李景青;;《海南医学》;20150110;26(01);43-45 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117771381A (en) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI574633B (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| CN112402459B (en) | Application of clostridium pralatum in relieving allergic asthma and rhinitis Th2 reaction | |
| CN113832062B (en) | Lactobacillus paracasei LC86 and application thereof in preventing or treating dental caries and periodontitis | |
| WO2018188124A1 (en) | Colonizing probiotic preparation, applications thereof, and medicament | |
| CN103918792A (en) | Xylitol probiotics goat milk tablets and preparation method thereof | |
| CN102389743A (en) | Formula of medical bacteriostatic humidifying solution | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN109512854B (en) | Probiotic composition for preventing and treating allergic rhinitis, nasal preparation based on same and preparation method | |
| CN115607577A (en) | Probiotic with effect of relieving stomatitis as well as preparation method and application thereof | |
| CN117771381B (en) | Nasal cavity active liquid and preparation method and application method thereof | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| JPH03198747A (en) | Disease-preventive feed and feed additive for cattle and pig | |
| CN111084155A (en) | Healthy breeding method for effectively preventing and controlling swine fever | |
| CN107646531A (en) | A kind of preparation method of Se-rich lucid ganoderma culture medium | |
| JP2021529816A (en) | Compositions Containing Bacterial Strains | |
| CN111358813B (en) | Salt fog mixture for protecting respiratory tract | |
| CN111743922B (en) | Composition for improving colonization and activity of probiotics in nasal cavity and application of composition in nasal cavity care | |
| CN115212290A (en) | Atomized inhalation type atomized liquid for preventing and treating virus infection and production method thereof | |
| CN115011513A (en) | Lactic acid bacteria powder for enhancing immunity, regulating intestines and stomach to control fat, losing weight and expelling toxin | |
| CN102941034A (en) | Medical humidification liquid having bacteriostasis function | |
| WO2018188123A1 (en) | Microbial adhesion-rate regulator and application thereof | |
| CN106727731A (en) | A kind of whole Enteral formulationses of Tiny ecosystem stomach invigorating and preparation method thereof | |
| CN111296842A (en) | Probiotic composition with anti-allergy effect | |
| TWI496578B (en) | Therapectic agent for influenza virus infection | |
| JP4591810B2 (en) | Nasal composition for controlling hay fever allergic rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |